Swedish Orphan Biovitrum AB Stock

Equities

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:29:53 2024-04-12 am EDT 5-day change 1st Jan Change
252.8 SEK -1.25% Intraday chart for Swedish Orphan Biovitrum AB -4.10% -5.32%
Sales 2024 * 24.11B 2.21B Sales 2025 * 26.8B 2.46B Capitalization 85.89B 7.89B
Net income 2024 * 3.52B 323M Net income 2025 * 4.86B 447M EV / Sales 2024 * 4.17 x
Net Debt 2024 * 14.74B 1.35B Net Debt 2025 * 9.56B 878M EV / Sales 2025 * 3.56 x
P/E ratio 2024 *
24.9 x
P/E ratio 2025 *
18.1 x
Employees 1,772
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.25%
1 week-4.10%
Current month-5.39%
1 month-9.84%
3 months-13.25%
6 months+14.70%
Current year-5.32%
More quotes
1 week
252.00
Extreme 252
268.80
1 month
252.00
Extreme 252
278.80
Current year
243.20
Extreme 243.2
302.00
1 year
197.90
Extreme 197.9
302.00
3 years
127.10
Extreme 127.1
302.00
5 years
127.10
Extreme 127.1
302.00
10 years
65.25
Extreme 65.25
302.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 17-05-21
Director of Finance/CFO 57 18-07-19
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 20-12-31
Chairman 70 14-05-07
Director/Board Member 55 19-12-31
More insiders
Date Price Change Volume
24-04-12 252.8 -1.25% 306,618
24-04-11 256 -1.16% 369,988
24-04-10 259 -2.78% 365,135
24-04-09 266.4 +1.68% 375,206
24-04-08 262 -0.61% 184,687

Delayed Quote Nasdaq Stockholm, April 12, 2024 at 11:29 am EDT

More quotes
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
252.8 SEK
Average target price
314.1 SEK
Spread / Average Target
+24.25%
Consensus